Quest Diagnostics stock: Quest raises 2026 guidance. What it means for Quest Diagnostics stock

Published on 10/23/2026 at 05:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Quest lifted 2026 revenue guidance to USD 12.065-12.105 billion on October 22, 2026. Quest Diagnostics stock saw Q3 revenue rise 10.0 percent.

Guidance and operating results

Quest lifted full-year revenue guidance to USD 12.065 billion to USD 12.105 billion on October 22, 2026.
Third-quarter revenue reached USD 3.097 billion, up 10.0 percent from the prior-year quarter.
Quest Diagnostics had a USD 26.9 billion market capitalization as of October 22, 2026.

Automatisierter Laboranalysator mit Blutproben-Röhrchen in klinischem Diagnostiklabor — Quest Diagnostics US74834L1008 zeigt automatisierten Laboranalysator mit Blutproben in modernem Diagnostiklabor fotorealistisch dargestellt, Illustration mit AI erstellt.

Quest Diagnostics raised its full-year 2026 revenue guidance to USD 12.065 billion to USD 12.105 billion after reporting third-quarter revenue of USD 3.097 billion, up 10.0 percent from the prior-year quarter, according to the company's Quest Diagnostics release dated October 22, 2026. The revised range compares with prior guidance of USD 11.95 billion to USD 12.05 billion.

What does the guidance change mean?

The update also lifted reported diluted earnings per share guidance to USD 10.21 to USD 10.31 from USD 9.97 to USD 10.17. Adjusted diluted earnings per share guidance moved to USD 11.25 to USD 11.35 from USD 11.05 to USD 11.25, while third-quarter adjusted earnings per share reached USD 3.00, according to the same October 22 release.

The operating picture added support to the higher outlook. Quest reported third-quarter net income of USD 312 million, up 27.6 percent year over year, while reported operating income rose to USD 479 million from USD 386 million. Adjusted operating margin reached 16.7 percent, compared with 16.3 percent in the prior-year quarter, according to the Benzinga transcript report.

Three dated developments

On October 6, 2026, Barclays raised its Quest target from USD 250.00 to USD 260.00 while keeping an Overweight rating, as reported by Business Insider. On October 19, 2026, UBS lifted its target from USD 245.00 to USD 250.00 and maintained Neutral, according to MarketScreener. The October 22 results then supplied the latest operating figure.

Next date is March 25, 2027

Quest Diagnostics will hold its 2027 Investor Day on March 25, 2027, at the New York Stock Exchange, according to the October 22 company release. The company said it plans to provide 2027 guidance with its fourth-quarter and full-year results early in 2027.

Market value and operating scale

Quest Diagnostics had a USD 26.9 billion market capitalization as of October 22, 2026. Its 52-week range stood at USD 171.18 to USD 248.84, while the company profile identifies healthcare as its sector and medical diagnostics and research as its industry.

Quest Diagnostics Incorporated is listed on the NYSE under ticker DGX. The company reported USD 611 million in operating cash flow for the third quarter of 2026, adding a cash-generation measure to the revenue and margin gains.

The further course of trading is shown by the continuously updated real-time quote of Quest Diagnostics stock.